Design, synthesis, and biological activity of certain quinazolinedione derivatives as potent phosphodiestrase4 inhibitors

Medicinal Chemistry Research

Volumn 21, Issue 11, 2012, Pages 3557-3567

  Elansary, Afaf K ^a   Kadry, Hanan H ^a   Ahmed, Eman M ^a   Sonousi, Amr Sayed Motawi ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Docking study; Phosphodiestase4B (PDE4b) inhibitor; Quinazolindiones; Synthesis

Indexed keywords

1 [2 (4 BROMOPHENYL) 2 OXOETHYL] 3 BUTYLQUINAZOLINE 2,4(1H,3H) DIONE; 1 BENZYL 3 BUTYLQUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 (2 OXO 2 PHENYLETHYL)QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (4 CHLOROPHENYL) 2 OXOETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (4 PHENYLPIPERAZIN 1 YL)ETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (DIETHYLAMINO)ETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (MORPHOLIN 4 YL)ETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (PIPERIDIN 1 YL)ETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [2 (PYRROLIDIN 1 YL)ETHYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 (DIETHYLAMINO)PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 (MORPHOLIN 4 YL)PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 (PIPERIDIN 1 YL)PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 (PYRROLIDIN 1 YL)PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; 3 BUTYL 1 [3 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL]QUINAZOLINE 2,4(1H,3H) DIONE; CYCLIC AMP; PHOSPHODIESTERASE IV INHIBITOR; QUINAZOLINE DERIVATIVE; ROLIPRAM; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CELL FUNCTION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROLYSIS; IN VITRO STUDY; MOLECULAR DOCKING;

EID: 84871408744     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9892-x     Document Type: Article

References (19)

1. Barnes PJ (1999) Therapeutic strategies for allergic diseases. Nature 402:B31-B38
2. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520
3. Blizzard TA, Marino G, Mrozik H, Fisher MH, Hoogsteen K, Springer JP (1989) Chemical modification of paraherquamide. 1. Unusual reactions and absolute stereochemistry. J Org Chem 54:2657-2663
4. Burnouf C, Pruniaux MP, Szilagyi CM (1998) Phosphodiesterase 4 inhibitors. In: Bristol JA (ed) Annual reports in medicinal chemistry. Academic Press, Michigan, pp 91-109
5. Clark RH, Wagner EC (1944) Isatoic anhydride. I. Reactions with primary and secondary amines and with some amides1. J Org Chem 9:55
6. Gadekar SM, Kotsen AM, Cohen E (1964) Anthranilamides as Intermediates for 3-Substituted Quinazoline-2,4-diones. J Chem Soc 4666-4668. http://pubs.rsc.org/en/content/articlelanding/1964/jr/jr9640004633
7. Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SLC, Conti M, Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35
8. McKenna JM, Muller GW (2006) Cyclic nucleotide phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Health and disease. CRC Press, pp 667-670
9. Molecular Operating Environment (MOE 2008.10); C.C.G., Inc., 1255 University St., Suite 1600, Montreal, Quebec, Canada H3B 3X3. 2005. http://www.chemcomp.com
10. Norman P (1999) PDE4 inhibitors. Exp Opin Ther Patents 9:1101-1117
11. Palacios JM, Beleta J, Segarra V (1995) Second messengers systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Farmaco 50:819-827
12. Piaz VD, Giovannoni MP (2000) Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 35:463-480
13. Potter BVL (1990) Transmembrane signalling second messenger analogues and inositol phosphates. In: Hansch C, Sammes PG, Taylor JB (eds) Comprehensive medicinal chemistry. Pergamon Press, Oxford, pp 102-128
14. Robichaud A, Stamatiou PB, Jin SLC, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC (2002) Deletion of phosphodiesterase 4D in mice shortens a2-Adrenoceptormediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:1045-1052
15. Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115
16. Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol 47:127-162
17. Staiger RP, Wagner EC (1953) Isatoic anhydride. III. Reactions with primary and secondary amines. J Org Chem 18:1427-1439
18. Torphy TJ (1998) Action of mediators on airway smooth muscle: functional antagonism as a mechanism for bronchodilator drugs. Agents Actions 23(Suppl):S37-S53
19. Zhang KYJ, Ibrahim PN, Gillette S, Bollag G (2005) Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 9:1283-1305